XOMA — XOMA Royalty Corp

Nasdaq · Health Care · Pharmaceuticals · CIK 791908 ·
Last close
$41.72
Market Cap
$523.21M
52W High
$42.81
52W Low
$24.48
ADV30
305,646
Next earnings
2026-05-13
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 310,000 -480,000 4,465,000 271,858,000 85,600,000 158,963,000
Dec 2025 1,432,000 2,182,000 6,103,000 272,698,000 82,908,000 188,757,000
Sep 2025 532,000 -1,330,000 14,051,000 263,151,000 45,189,000 155,194,000
Jun 2025 5,379,000 4,603,000 9,191,000 223,456,000 75,060,000 131,002,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$2,871,000
Investing CF
$50,886,000
Financing CF
$-26,463,000
CapEx
$-114,000
Dividends Paid
$-5,472,000
Buybacks
$-16,715,000
EPS Diluted TTM
$1.46
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,221,450,000
Inventory
Receivables
$27,676,000
ST Investments
$382,000
EBIT TTM
$44,846,000
Pretax Income TTM
$31,815,000
Interest Exp TTM
$13,031,000
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$48,555,000
EBITDA
$8,295,000
Free Cash Flow
$-13,069,500
Enterprise Value
$581,917,760
Total Cash
$86,094,000
Total Debt
$124,732,000
Shares Out
12,541,030
Trailing EPS
$1.57
Book Value
$7.07
ROE
34.2%
ROA
1.3%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 11,660,000 11,384,000 31,712,000 272,698,000 188,757,000 2,871,000
Dec 2024 10,220,000 -39,976,000 -13,821,000 221,277,000 159,375,000 -13,748,000
Dec 2023 4,758,000 -23,463,000 -40,831,000 234,301,000 145,580,000 -18,158,000
Dec 2022 6,027,000 -17,414,000 -17,104,000 140,382,000 16,368,000 -12,879,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$2.14

Peers — same industry

TickerNameMarket CapLastDaily %
PRTA PROTHENA CORP PUBLIC LTD CO $526.67M $10.06
NIKA NIKA PHARMACEUTICALS, INC $534.76M $0.51
AQST Aquestive Therapeutics, Inc. $511.84M $4.08
RIGL RIGEL PHARMACEUTICALS INC $539.71M $29.17
EPRX EUPRAXIA PHARMACEUTICALS INC. $491.91M $7.53

News headlines (Yahoo Finance, 1h cache)

Oncobiologics, Inc. (OTLK) Reports Q2 Loss, Lags Revenue Estimates
2026-05-15 21:25 · Yahoo
Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates
2026-05-11 22:05 · Yahoo
CG Oncology, Inc. (CGON) Reports Q1 Loss, Tops Revenue Estimates
2026-05-08 13:35 · Yahoo
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates
2026-05-07 12:50 · Yahoo
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue Estimates
2026-05-06 22:30 · Yahoo
XOMA Royalty (XOMA) Moves 10.7% Higher: Will This Strength Last?
2026-04-28 09:53 · Yahoo
Royalty Powerhouse: Ligand And Xoma Unite In $739 Million Deal
2026-04-27 20:11 · Yahoo
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
2026-04-27 11:00 · Yahoo
We Believe XOMA Royalty's (NASDAQ:XOMA) Earnings Are A Poor Guide For Its Profitability
2026-03-26 10:51 · Yahoo
XOMA Royalty Q4 Earnings Call Highlights
2026-03-18 23:20 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.